This is the program for the 2010 Joint Statistical Meetings in Vancouver, British Columbia.

Keyword Search

Keyword Search Criteria: maximum tolerated dose returned 7 record(s)
Sunday, 08/01/2010
Better Learning About the MTD in Phase I Oncology Trial: A Case Study Implementing Bayesian Design Based on Continuous Reassessment Method
Inna Perevozskaya, Pfizer Inc.
2:25 PM

Bivariate Semiparametric Bayesian Approach for Finding Minimum Effective Dose and Maximum Safe Dose
Satrajit Roychoudhury, Novartis Pharmaceuticals Corporation; Pulak Ghosh, Indian Institute of Management, Bangalore
2:45 PM

Monday, 08/02/2010
Comparisons of Methods in Phase I Dose-Escalation Clinical Trial Designs
Liping Huang, Bayer HealthCare Pharmaceuticals


A Conditional Bayesian Logistic Regression Model (BLRM) with Overdose Control
Lu-May Chiang, Novartis Pharmaceuticals Corporation; Adarsh Joshi, Eli Lilly and Company; David Ohlssen, Novartis Pharmaceuticals Corporation; Jyotirmoy Dey, Novartis Pharmaceuticals Corporation
9:05 AM

Tuesday, 08/03/2010
Who Needs Bayesian Phase I Trials?
Rick Chappell, University of Wisconsin-Madison
2:30 PM

Wednesday, 08/04/2010
Stopping Rules for Bayesian Dose-Finding Oncology Trials
Yanqiong Zhang, Sanofi-Aventis; Yi He, sanofi-aventis; Guillaume Marchand, sanofi-aventis; Pierre Mancini, sanofi-aventis; Sandrine Micallef, sanofi-aventis
10:50 AM

Dose-Escalation Approaches for Two Agents in Early-Phase Oncology Studies
Yevgen Tymofyeyev, Merck & Co., Inc.; Christine K. Gause, Merck Research Laboratories; Keaven M. Anderson, Merck Research Laboratories
11:50 AM




2010 JSM Online Program Home

For information, contact jsm@amstat.org or phone (888) 231-3473.

If you have questions about the Continuing Education program, please contact the Education Department.